查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863344

下一代肿瘤治疗设备和解决方案市场（按设备类型、技术、癌症类型和最终用户划分）—2025-2032年全球预测

Next-Generation Oncology Devices & Solutions Market by Device Type, Technology, Cancer Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，下一代肿瘤设备和解决方案市场将成长至 911.8 亿美元，复合年增长率为 21.67%。

关键市场统计数据
基准年 2024 189.7亿美元
预计年份：2025年 230.5亿美元
预测年份 2032 911.8亿美元
复合年增长率 (%) 21.67%

肿瘤治疗设备和解决方案领域正迈入一个以技术融合、临床精准化和以患者为中心的工作流程为特征的新时代。分子诊断、影像学和设备自动化的进步正推动肿瘤治疗从间歇性干预转向持续的、数据驱动的管理。因此，临床路径正在重组，早期检测、更精确的肿瘤表征和自适应治疗方法方案正被整合到常规实践中。这种变革并非局限于单一技术领域，而是涵盖诊断、影像、监测、手术和治疗设备等多个学科，并将它们整合起来，从而实现封闭回路型肿瘤治疗。

从概念验证到广泛的临床应用，需要生产製造、监管策略、报销途径和机构采购等各环节的协调一致。相关人员必须应对诸多挑战，例如日益增长的临床证据要求、与医疗资讯科技系统的互通性以及与医疗团队的无缝整合。因此，那些能够将严谨的临床检验与切实可行的商业化计划相结合，密切关注医护人员工作流程，并能够向支付方和医疗系统证明其真实价值的机构，将最有可能取得成功。

人工智慧、基因组学、影像学和微创技术等新兴趋势相互融合，正在重新定义癌症治疗的临床路径和商业模式。

临床实务的根本转变、技术的成熟、策略市场力量的汇聚，正加速肿瘤医疗器材生态系统的转型。人工智慧和进阶分析不再是小众技术，而是能够提升影像解读效率、优化病理工作流程并优先考虑基因组学观察以指导治疗方案选择的实用工具。同时，次世代定序和数位病理技术正在缩短诊断週期，并实现多模态资料整合，从而支持精准医疗。

同时，成像系统正朝着更高解析度、混合模式以及提供定量生物标记的方向发展，以改善病灶表征和治疗反应评估。穿戴式生物感测器和连续监测平台正在改变我们与患者的互动方式，并实现对治疗耐受性的远端评估。手术机器人和微创技术提高了手术的精准度，同时缩短了恢復时间。总而言之，这些变革正在改变癌症治疗的提供、资金筹措和评估方式，影响临床工作流程、资金配置和竞争格局。

关税政策变化对癌症治疗技术策略影响评估：全球供应链动态、设备设计、监管合规和定价

2025年美国关税政策为肿瘤设备和解决方案领域的企业带来了新的营运和策略考量。在製造层面，进口零件和组件成本的增加影响了费用结构，促使企业重新评估全球筹资策略。许多製造商正在考虑近岸外包、双重采购以及建立在地采购网络，以降低关税造成的成本波动风险。因此，供应链设计正从单纯的成本优化转向以韧性为中心的模式，强调时间安排、库存策略和合约方面的灵活性。

除了采购之外，关税也在加速设备架构的重新设计和材料清单(BOM) 的简化。工程团队正在寻求模组化设计，以减少对关税敏感组件的依赖，并优先考虑能够实现替代采购的标准化介面。监管和品管团队也被迫做出调整，组件替换和供应商变更需要及时记录和检验，以确保合规性。在商业方面，与医疗系统和集团采购组织的价格谈判变得日益复杂，要求製造商透过透明的总拥有成本解释和基于价值的合约方式来证明成本增加的合理性。最后，投资者和企业负责人正在重新评估资本支出计画和併购活动，以精简供应链、保护智慧财产权，并在能够降低关税风险的地区加强製造地。

按设备、技术、癌症类型和最终用户进行细分，揭示了肿瘤治疗领域不同的发展重点和应用趋势。

了解肿瘤医疗器材细分市场的细微差别对于指导产品开发重点和商业化路径至关重要。医疗器材分类包括：诊断系统，例如免疫组织化学和萤光杂合反应；分子平台，例如聚合酵素链锁反应(PCR)，包括数位 PCR 和定量 PCR；以及次世代定序(NGS)，涵盖EXOME定序、标靶基因组定序和全基因测序方法。影像技术涵盖了从锥状射束和多切面螺旋电脑断层扫描 (CT) 平台到 1.5T 和 3T 磁场强度的磁振造影(MRI) 系统，以及正子断层扫描 (PET) 解决方案，包括 PET/CT 和 PET/MRI 混合设备。超音波设备涵盖了从传统二维成像到先进的三维和四维成像功能，X 射线系统则包括电脑放射成像 (CR)数位放射线放射成像 (DR)。监测解决方案越来越多地整合生物感测器和可穿戴设备，以实现长期数据收集。我们的外科手术器械包括冷冻手术器械、腹腔镜技术和支援精准介入手术的机器人平台。我们的治疗设备产品组合涵盖药物传输系统和放射治疗设备，而我们的放射治疗解决方案则包括近距离近距离放射系统、直线加速器和质子治疗机。

技术主导的细分进一步明确了采用路径和投资重点。人工智慧正透过数据分析、深度学习和机器学习得到应用，旨在提高诊断准确性和营运效率。生物资讯能力围绕着次世代定序资料分析和蛋白质体学流程展开，而数位病理学投资则专注于影像分析软体和全切片成像平台。奈米技术的发展包括用于靶向递送的奈米载体和用于提高灵敏度的奈米诊断技术。机器人技术继续区分专用活检系统和针对切片检查工作流程优化的手术机器人。按癌症类型（例如乳癌、结直肠癌、肺癌和前列腺癌）分類的临床重点影响着诊断和治疗的优先顺序，而最终用户细分（包括门诊中心、诊断实验室、医院和研究机构）则决定了采购週期、IT整合需求和实施所需的证据。整合这些细分层级使产品团队和商业领导者能够针对不同的临床和组织购买者需求，并制定相应的功能集、临床检验计划和服务模式。

区域比较分析突显了法规结构、临床基础设施和製造地对肿瘤医疗器材应用和市场发展路径的影响

区域趋势对癌症医疗器材和解决方案的监管要求、上市时间表和商业化路径有显着影响。在美洲，完善的临床试验基础设施、众多专业癌症中心以及重视临床和经济价值证据的支付方环境，正在加速创新诊断方法和医疗器材的普及应用。该地区也是医疗器材製造和风险投资的热点地区，这既有利于快速的商业化週期，也要求严格的上市后监测和真实世界证据的累积。

欧洲、中东和非洲地区呈现多元化的格局，监管协调工作与各国特有的报销流程和采购行为并存。在一些市场，集中核准和基于价值的采购机制促进了跨境应用，而其他地区（中东除外）的资源限制则要求采用成本效益高且可扩展的解决方案。该地区复杂的报销结构和多样化的临床实践模式凸显了模组化产品模式和灵活商业策略的重要性。亚太地区拥有庞大的市场规模，同时技术应用迅速，本地製造能力不断提升，并且公共对精准医疗进行了战略性投资。亚太主要市场的监管机构正日益接受对具有高临床效用的医疗设备的加速核准途径，使区域製造商能够成为全球供应链中具有竞争力的供应商。在所有地区，医疗器材的应用都受到当地劳动力能力、数位基础设施成熟度以及支持早期检测、患者就医和癌症监测的国家政策重点的影响。

现有平台公司、专业创新者和策略联盟正透过整合解决方案、智慧财产权策略和服务主导的差异化重新定义竞争格局。

肿瘤医疗设备和解决方案领域的竞争格局呈现出多元化的特点，既有大型平台供应商，也有专注于技术的专业公司，还有致力于提供以临床为导向的创新产品的敏捷型Start-Ups。成熟的医疗技术公司利用其广泛的商业管道、服务网路和监管经验，扩展其整合的硬体、软体和服务解决方案。同时，一些专注于特定领域的公司往往在分子诊断、数位病理学和机器人等领域推进颠覆性技术，迫使现有企业透过合作、授权或进行有针对性的收购来维持其临床竞争力。

在寻求建构端到端价值提案的企业中，医疗设备製造商、软体公司和临床研究机构之间的策略联盟正变得越来越普遍。以演算法、设备介面和组件设计为核心的智慧财产权组合是关键的差异化因素，而生产规模和供应商关係则构成了成本竞争力的基础。此外，越来越多的公司正在拓展产品范围，涵盖资讯服务、临床决策支援和生命週期管理，从而创造持续的收入来源并加深客户参与。对于销售团队而言，了解竞争对手在证据产生、报销支援和售后服务方面的定位，对于建构制胜的价值提案至关重要。

经营团队需应对一系列切实可行的策略挑战，包括加强供应链、收集证据、实现产品模组化以及建构商业模式，以确保可持续的竞争优势。

产业领导者必须采取多管齐下的策略，抓住下一代肿瘤治疗设备带来的机会，同时降低系统性风险。首先，供应链韧性应成为策略重点。供应商多元化、尽可能投资近岸製造以及重新设计产品以提高组件弹性，都能降低政策驱动型干扰所带来的风险。同时，企业应优先产生符合支付方要求和机构采购标准的可靠临床和卫生经济学证据。儘早与临床医生、卫生技术评估机构和支付方决策者合作，可以确保研究设计和资料收集能够涵盖最相关的终点指标。

产品策略应强调互通性、模组化和软体驱动的升级路径，以支援延长产品生命週期和逐步推出新功能。销售部门应制定符合医疗服务提供者奖励的定价和合约模式（包括在适当情况下采用按绩效付费合约），并加强销售能力，以支持医院和研究机构复杂的销售週期。对上市后资料收集和真实世界证据平台的投资，不仅可以增强监管和报销审查资料，还能为迭代式产品改进提供可操作的见解。最后，组织优先事项应包括人才策略，以吸引临床、监管和数位化领域的专业人才，并建立一种强调快速、循证迭代的企业文化，以跟上临床创新的步伐。

调查方法结合了专家访谈、监管和临床证据审查以及多方面的检验，以确保获得可靠且实用的见解。

本分析所依据的研究采用多层调查方法，以确保研究的严谨性、多方验证以及与相关人员的相关性。主要研究包括对医疗设备製造商和医院系统的临床意见领袖、采购负责人、监管专家和高阶主管进行结构化访谈。这些定性研究结果辅以对公开的监管文件、临床试验註册资讯、同行资讯披露文献和专利揭露的系统性审查，以识别技术趋势和证据缺口。此外，还透过分析公司新闻稿、产品公告和投资者报告，进一步检验了市场和技术趋势，以了解其策略意图和资源分配。

定量分析辅以资料集综合和交叉检验程序，以确保资讯来源的一致性。必要时，进行敏感度分析和情境测试，以探讨不同法规环境和政策环境下的影响。整个过程实施了品管，包括资讯来源重的调查方法标准、领域专家的同侪审查以及保护访谈隐私的伦理保障措施。研究承认并克服了其局限性，透过收集不同地区、技术成熟度水准和製度背景下的多元观点，确保结论稳健可靠，并能为决策者提供切实可行的指导。

摘要重点介绍了整合的临床平台、实证商业化以及应对政策和区域差异的能力。

摘要，下一代肿瘤设备和解决方案将由整合高精度诊断、先进影像、智慧软体和微创治疗的平台构成，从而建立临床路径。能够将卓越技术与临床证据、监管前瞻性和灵活的商业模式相结合的机构将获得成功。关税政策的波动、区域监管差异以及不断变化的支付方预期等外部因素将继续影响策略选择，进一步提升对适应性供应链和基于价值的定价方法的需求。

积极主动地将产品策略与临床工作流程相结合、投资生成真实世界数据 (RWE) 并促进整个生态系统伙伴关係的相关人员，将更有利于加速精准肿瘤学的普及应用并充分发挥其潜力。相反，那些研发结构缺乏跨职能协调、对上市后数据投入不足或未能预见政策主导的成本压力的公司，则可能面临普及速度放缓和利润率下降的风险。未来的道路需要严谨的执行、跨职能的协作，以及始终专注于向病患、医疗服务提供者和支付者展现切实的临床和经济价值。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧成像技术与即时肿瘤边缘检测相结合应用于外科肿瘤学
  • 开发用于早期癌症检测和监测的多重液态生物检体检测方法
  • 利用穿戴式生物感测器连续监测化疗引起的心臟毒性
  • 基于奈米颗粒的固态肿瘤靶向药物递送系统的研究进展
  • 推出云端基础的平台，用于安全地共用癌症患者的基因组数据
  • 黑色素瘤患者个人化免疫疗法选择的伴随诊断技术的发展
  • 低场可携式磁振造影系统在偏远诊所照护现场肿瘤表征的应用

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 下一代肿瘤设备和解决方案市场（按设备类型划分）

  • 诊断设备
    • 萤光原位杂合反应
    • 免疫组织化学
    • 次世代定序
      • EXOME定序
      • 目标面板
      • 全基因测序
    • 聚合酵素链锁反应
      • 数位PCR
      • 定量PCR
  • 诊断影像设备
    • 电脑断层扫描
      • 锥状射束CT
      • 多切面CT
    • 磁振造影
      • 1.5T成像
      • 3T成像
    • 正子断层扫描
      • PET/CT混合
      • PET/MRI混合
    • 超音波影像
      • 二维成像
      • 3D/4D成像
    • X光影像诊断
      • 电脑放射成像
      • 数位放射线
  • 监控设备
    • 生物感测器
    • 穿戴式装置
  • 手术器械
    • 冷冻手术
    • 腹腔镜手术
    • 机器人手术
  • 治疗设备
    • 药物输送装置
    • 放射治疗设备
      • 近距离放射系统
      • 直线加速器
      • 质子治疗系统

9. 按技术分類的下一代肿瘤设备和解决方案市场

  • 人工智慧
    • 数据分析
    • 深度学习
    • 机器学习
  • 生物资讯学
    • 次世代定序（NGS）资料分析
    • 蛋白质体学数据分析
  • 数位病理学
    • 影像分析软体
    • 全切片成像
  • 奈米科技
    • 奈米载体
    • 奈米诊断
  • 机器人技术
    • 切片检查机器人
    • 手术机器人

第十章：按癌症类型分類的下一代肿瘤设备和解决方案市场

  • 乳癌
  • 大肠直肠癌
  • 肺癌
  • 摄护腺癌

第十一章：按最终用户分類的下一代肿瘤设备和解决方案市场

  • 门诊治疗中心
  • 诊断实验室
  • 医院
  • 研究所

12. 下一代肿瘤设备和解决方案市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：按组别分類的下一代肿瘤设备和解决方案市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国下一代肿瘤设备与解决方案市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Siemens Healthineers AG
    • General Electric Company
    • Koninklijke Philips NV
    • Accuray Incorporated
    • Ion Beam Applications SA
    • Brainlab AG
    • ViewRay, Inc.
    • Mevion Medical Systems, Inc.
    • RaySearch Laboratories AB
Product Code: MRR-2E76C3E47F6D

The Next-Generation Oncology Devices & Solutions Market is projected to grow by USD 91.18 billion at a CAGR of 21.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.97 billion
Estimated Year [2025] USD 23.05 billion
Forecast Year [2032] USD 91.18 billion
CAGR (%) 21.67%

The oncology devices and solutions landscape is entering an era defined by technological convergence, clinical precision, and a relentless drive toward patient-centered workflows. Advances in molecular diagnostics, imaging modalities, and device automation are moving oncology care from episodic intervention toward continuous, data-driven management. As a result, clinical pathways are being reconfigured to embed earlier detection, more accurate tumor characterization, and adaptive therapeutic delivery in routine practice. This evolution is not limited to a single technology class; instead, it spans diagnostic, imaging, monitoring, surgical, and therapeutic devices that together enable closed-loop oncologic care.

Transitioning from proof of concept to widespread clinical adoption requires alignment across manufacturing, regulatory strategy, reimbursement pathways, and institutional procurement. Stakeholders must navigate heightened expectations for clinical evidence, interoperability with health IT systems, and seamless integration into care teams. Consequently, the most successful organizations will be those that combine rigorous clinical validation with pragmatic commercialization plans, an acute sensitivity to provider workflows, and an ability to demonstrate real-world value to payers and health systems.

How emerging AI, genomics, imaging, and minimally invasive technologies are converging to redefine clinical pathways and commercial models in oncology care

Fundamental shifts in clinical practice, technology maturation, and strategic market behavior are collectively accelerating transformation across the oncology device ecosystem. Artificial intelligence and advanced analytics are no longer niche capabilities; they are operational tools that enhance image interpretation, streamline pathology workflows, and prioritize genomic findings for treatment selection. Concurrently, next-generation sequencing and digital pathology are reducing diagnostic turnaround times and enabling multi-modal data synthesis that supports precision medicine.

In parallel, imaging systems have evolved to offer higher resolution, hybrid modalities, and quantitative biomarkers that improve lesion characterization and response assessment. Wearable biosensors and continuous monitoring platforms are transforming patient engagement and enabling remote assessment of therapy tolerability. Surgical robotics and minimally invasive techniques are refining procedural accuracy while reducing recovery time. Taken together, these shifts are changing how oncology care is delivered, financed, and measured, with implications for clinical workflows, capital allocation, and the competitive landscape.

Assessing the strategic consequences of tariff policy shifts on global supply chains, device design, regulatory compliance, and pricing dynamics across oncology technologies

The implementation of United States tariffs in 2025 has introduced a new set of operational and strategic considerations for companies involved in oncology devices and solutions. At the manufacturing level, cost structures have been affected by increased expenses for imported components and subassemblies, which in turn has encouraged a reassessment of global sourcing strategies. Many manufacturers are evaluating nearshoring, dual-sourcing, and localized supplier networks to mitigate exposure to tariff-driven cost volatility. As a consequence, supply chain design has shifted from a pure cost-optimization focus to a resilience-centric model that emphasizes timing, inventory strategies, and contractual flexibility.

Beyond procurement, tariffs have accelerated redesign efforts for device architecture and bill-of-material simplification. Engineering teams are seeking modular designs that reduce reliance on tariff-sensitive components and prioritize standardized interfaces to enable alternative sourcing. Regulatory affairs and quality teams are also adapting, as component substitutions and supplier changes require timely documentation and revalidation to maintain compliance. On the commercial front, pricing negotiations with health systems and group purchasing organizations have become more complex, with manufacturers needing to substantiate cost increases through transparent total cost of ownership narratives and value-based contracting approaches. Finally, investors and corporate strategists are reassessing capex plans and M&A activity to capture supply chain efficiencies, secure intellectual property, and shore up manufacturing footprints in jurisdictions that reduce tariff exposure.

Unpacking device, technology, cancer type, and end user segmentation to reveal differentiated development priorities and adoption dynamics across oncology care

A nuanced understanding of segmentation is essential to navigate product development priorities and commercialization pathways across oncology devices. Device classifications span diagnostic systems such as immunohistochemistry and fluorescence in situ hybridization, molecular platforms including polymerase chain reaction with digital and quantitative PCR formats, and next-generation sequencing which itself encompasses exome sequencing, targeted panels, and whole genome sequencing approaches. Imaging technologies range from computed tomography platforms with cone beam and multi-slice configurations to magnetic resonance imaging systems offered in 1.5T and 3T field strengths, alongside positron emission tomography solutions available as PET/CT and PET/MRI hybrids. Ultrasound offerings vary from conventional two-dimensional imaging to advanced three-dimensional and four-dimensional capabilities, while X-ray systems exist in computed radiography and digital radiography forms. Monitoring solutions increasingly incorporate biosensors and wearable devices to enable longitudinal data capture, whereas surgical tools include cryosurgery, laparoscopic techniques, and robotic platforms that support precision interventions. Therapeutic device portfolios cover drug delivery systems and radiation therapy modalities, with radiation solutions spanning brachytherapy systems, linear accelerators, and proton therapy installations.

Technology-driven segmentation further clarifies adoption pathways and investment focus. Artificial intelligence is being applied through data analytics, deep learning, and machine learning to enhance diagnostic yield and operational efficiency. Bioinformatics capabilities are centered on next-generation sequencing data analysis and proteomics pipelines, while digital pathology investments emphasize image analysis software and whole slide imaging platforms. Nanotechnology development includes nanocarriers for targeted delivery and nanodiagnostics to improve sensitivity, and robotics continues to differentiate into biopsy-specific systems and surgical robotics optimized for oncology workflows. Clinical focus across cancer types-such as breast, colorectal, lung, and prostate cancers-affects diagnostic and therapeutic priorities, and end-user segmentation encompassing ambulatory care centers, diagnostic laboratories, hospitals, and research institutes determines procurement cycles, IT integration needs, and evidence requirements for adoption. Synthesizing these layers of segmentation enables product teams and commercial leaders to target feature sets, clinical validation plans, and service models that align with distinct clinical and institutional buyer needs.

Comparative regional analysis revealing how regulatory frameworks, clinical infrastructure, and manufacturing footprints influence oncology device adoption and market pathways

Regional dynamics exert a powerful influence on regulatory expectations, adoption timelines, and commercialization pathways across oncology devices and solutions. In the Americas, strong clinical trial infrastructure, a concentration of specialized cancer centers, and payer environments that increasingly reward evidence of clinical and economic value combine to accelerate uptake of innovative diagnostics and devices. This region also remains a focal point for device manufacturing and venture investment, which supports rapid commercialization cycles while demanding robust post-market surveillance and real-world evidence generation.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization initiatives coexist with country-specific reimbursement processes and procurement behaviors. In some markets, centralized approvals and value-based procurement mechanisms encourage cross-border adoption, whereas resource constraints in other jurisdictions necessitate cost-effective, scalable solutions. The region's complex reimbursement tapestry and diverse clinical practice patterns place a premium on modular product models and flexible commercial strategies. Asia-Pacific exhibits a blend of high-volume markets with fast technology adoption, alongside growing local manufacturing capability and strategic public investments in precision medicine. Regulatory authorities in key Asia-Pacific markets are increasingly receptive to expedited pathways for devices demonstrating strong clinical utility, and regional manufacturers are becoming competitive suppliers for global supply chains. Across all regions, adoption is shaped by local workforce capacity, digital infrastructure maturity, and national policy priorities that support early detection, patient access, and cancer research.

How incumbent platforms, focused innovators, and strategic collaborations are redefining competition through integrated solutions, IP positioning, and service-driven differentiation

The competitive landscape in oncology devices and solutions is defined by a mix of large platform providers, specialized technology companies, and agile startups that bring focused innovations to clinical practice. Established medical technology firms leverage broad commercial channels, service networks, and regulatory experience to scale integrated solutions that combine hardware, software, and servicing. Meanwhile, niche companies often advance disruptive capabilities in areas such as molecular diagnostics, digital pathology, and robotics, forcing incumbents to pursue partnerships, licensing agreements, or targeted acquisitions to retain clinical relevance.

Strategic collaborations between device manufacturers, software companies, and clinical research organizations are increasingly common as firms seek to assemble end-to-end value propositions. Intellectual property portfolios centering on algorithms, device interfaces, and component designs serve as key differentiators, while manufacturing scale and supplier relationships underpin cost competitiveness. Moreover, a growing number of companies are expanding offerings beyond product delivery to include data services, clinical decision support, and lifecycle management, thereby creating recurring revenue streams and deeper customer engagement. For commercial teams, understanding competitor positioning across evidence generation, reimbursement support, and aftermarket services is critical to crafting winning value propositions.

Actionable strategic imperatives for executives to strengthen supply chains, evidence generation, product modularity, and commercial models to secure lasting competitive advantage

Industry leaders must adopt a multi-dimensional approach to capture the opportunities presented by next-generation oncology devices while mitigating systemic risks. First, supply chain resilience should be elevated to strategic priority status; diversifying suppliers, investing in near-shore manufacturing where feasible, and redesigning products for component flexibility will reduce exposure to policy-driven disruptions. Simultaneously, companies should prioritize the generation of robust clinical and health economic evidence that aligns with payer requirements and institutional procurement criteria. Early engagement with clinicians, health technology assessment bodies, and payer decision-makers ensures that trial designs and data collection address the most relevant endpoints.

Product strategy should emphasize interoperability, modularity, and software-enabled upgrade paths to extend product lifecycles and support incremental feature deployment. Commercial teams need to craft pricing and contracting models that align provider incentives, including outcomes-based agreements where appropriate, and to build commercial capabilities that support complex sales cycles within hospitals and research institutes. Investing in post-market data capture and real-world evidence platforms not only strengthens regulatory and reimbursement dossiers but also supplies actionable insights for iterative product improvement. Finally, organizational priorities should include talent strategies that attract clinical, regulatory, and digital expertise, and a culture that values rapid evidence-driven iteration to keep pace with clinical innovation.

Methodological framework combining expert interviews, regulatory and clinical evidence review, and multi-source triangulation to ensure robust and actionable insights

The research underpinning this analysis relied on a layered methodology intended to ensure rigor, triangulation, and relevance to stakeholders. Primary research included structured interviews with clinical opinion leaders, procurement professionals, regulatory experts, and senior executives across device manufacturers and hospital systems. These qualitative inputs were complemented by a systematic review of publicly available regulatory filings, clinical trial registries, peer-reviewed literature, and patent disclosures to identify technology trajectories and evidence gaps. Market and technology signals were further validated through analysis of company press releases, product launch materials, and investor presentations to capture strategic intent and resource allocation.

Quantitative analysis was supported by dataset integration and cross-validation routines to ensure consistency across sources. Where appropriate, sensitivity analyses and scenario testing were used to explore implications under different regulatory or policy environments. Throughout the process, quality controls included methodological rubrics for source weighting, peer review by domain experts, and ethical safeguards to protect interview confidentiality. Limitations of the research were acknowledged and addressed by seeking diverse viewpoints across geographies, technology maturity levels, and institutional contexts, ensuring that conclusions are robust and actionable for decision-makers.

Concluding synthesis emphasizing integrated clinical platforms, evidence-driven commercialization, and resilience in the face of policy and regional variability

In summary, the next wave of oncology devices and solutions will be defined by platforms that integrate high-fidelity diagnostics, advanced imaging, intelligent software, and minimally invasive therapeutics into coherent clinical pathways. Success will favor organizations that can harmonize engineering excellence with clinical evidence, regulatory foresight, and flexible commercial models. External forces such as tariff policy shifts, regional regulatory variability, and evolving payer expectations will continue to shape strategic choices, reinforcing the need for adaptable supply chains and value-based pricing approaches.

Stakeholders that proactively align product strategies with clinical workflows, invest in real-world evidence generation, and cultivate partnerships across the ecosystem will be best positioned to accelerate adoption and realize the promise of precision oncology. Conversely, firms that maintain siloed development, under-invest in post-market data, or fail to anticipate policy-driven cost pressures risk slower uptake and margin compression. The path forward requires disciplined execution, cross-functional coordination, and a relentless focus on demonstrating tangible clinical and economic value to patients, providers, and payers alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-powered imaging with real-time tumor margin detection in surgical oncology
  • 5.2. Development of multiplexed liquid biopsy assays for early-stage cancer detection and monitoring
  • 5.3. Adoption of wearable biosensors for continuous monitoring of chemotherapy-induced cardiotoxicity
  • 5.4. Advancements in nanoparticle-based targeted drug delivery systems for solid tumors
  • 5.5. Implementation of cloud-based platforms for secure sharing of oncology patient genomic data
  • 5.6. Growth of companion diagnostics for personalized immunotherapy selection in melanoma patients
  • 5.7. Emergence of low-field portable MRI systems for point-of-care tumor characterization in remote clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Next-Generation Oncology Devices & Solutions Market, by Device Type

  • 8.1. Diagnostic Devices
    • 8.1.1. Fluorescence In Situ Hybridization
    • 8.1.2. Immunohistochemistry
    • 8.1.3. Next Generation Sequencing
      • 8.1.3.1. Exome Sequencing
      • 8.1.3.2. Targeted Panels
      • 8.1.3.3. Whole Genome Sequencing
    • 8.1.4. Polymerase Chain Reaction
      • 8.1.4.1. Digital PCR
      • 8.1.4.2. Quantitative PCR
  • 8.2. Imaging Devices
    • 8.2.1. Computed Tomography
      • 8.2.1.1. Cone Beam CT
      • 8.2.1.2. Multi-Slice CT
    • 8.2.2. Magnetic Resonance Imaging
      • 8.2.2.1. 1.5T Imaging
      • 8.2.2.2. 3T Imaging
    • 8.2.3. Positron Emission Tomography
      • 8.2.3.1. PET/CT Hybrid
      • 8.2.3.2. PET/MRI Hybrid
    • 8.2.4. Ultrasound Imaging
      • 8.2.4.1. 2D Imaging
      • 8.2.4.2. 3D/4D Imaging
    • 8.2.5. X-Ray Imaging
      • 8.2.5.1. Computed Radiography
      • 8.2.5.2. Digital Radiography
  • 8.3. Monitoring Devices
    • 8.3.1. Biosensors
    • 8.3.2. Wearable Devices
  • 8.4. Surgical Devices
    • 8.4.1. Cryosurgery
    • 8.4.2. Laparoscopic Surgery
    • 8.4.3. Robotic Surgery
  • 8.5. Therapeutic Devices
    • 8.5.1. Drug Delivery Devices
    • 8.5.2. Radiation Therapy Devices
      • 8.5.2.1. Brachytherapy Systems
      • 8.5.2.2. Linear Accelerators
      • 8.5.2.3. Proton Therapy Systems

9. Next-Generation Oncology Devices & Solutions Market, by Technology

  • 9.1. Artificial Intelligence
    • 9.1.1. Data Analytics
    • 9.1.2. Deep Learning
    • 9.1.3. Machine Learning
  • 9.2. Bioinformatics
    • 9.2.1. NGS Data Analysis
    • 9.2.2. Proteomics Data Analysis
  • 9.3. Digital Pathology
    • 9.3.1. Image Analysis Software
    • 9.3.2. Whole Slide Imaging
  • 9.4. Nanotechnology
    • 9.4.1. Nanocarriers
    • 9.4.2. Nanodiagnostics
  • 9.5. Robotics
    • 9.5.1. Biopsy Robotics
    • 9.5.2. Surgical Robotics

10. Next-Generation Oncology Devices & Solutions Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Lung Cancer
  • 10.4. Prostate Cancer

11. Next-Generation Oncology Devices & Solutions Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Next-Generation Oncology Devices & Solutions Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Next-Generation Oncology Devices & Solutions Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Next-Generation Oncology Devices & Solutions Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Siemens Healthineers AG
    • 15.3.2. General Electric Company
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Accuray Incorporated
    • 15.3.5. Ion Beam Applications S.A.
    • 15.3.6. Brainlab AG
    • 15.3.7. ViewRay, Inc.
    • 15.3.8. Mevion Medical Systems, Inc.
    • 15.3.9. RaySearch Laboratories AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY TARGETED PANELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CONE BEAM CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MULTI-SLICE CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 1.5T IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3T IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/CT HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY PET/MRI HYBRID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY 3D/4D IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY COMPUTED RADIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY SURGICAL DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY CRYOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY LAPAROSCOPIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY ROBOTIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY DRUG DELIVERY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY RADIATION THERAPY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOLUTIONS MARKET SIZE, BY BRACHYTHERAPY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEXT-GENERATION ONCOLOGY DEVICES & SOL